Diabetes Year In Review 2017
The FDA has approved semaglutide injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Type 2 diabetes risk is increased in young adults through antidepressant use, specifically the duration of use and the cumulative dose.
Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.
After the inclusion of recent negative studies, a statistically significant association between AD use and diabetes was observed.
The statement includes advances in care since the ADA's last position statement was published in 2003.
Lifestyle interventions maintain glycemic control in patients with type 2 diabetes.
Consumption of alcohol 3 to 4 days weekly is associated with a significantly lower risk for diabetes in men and women.
Adulthood weight gain is associated with an increased risk of major chronic diseases and mortality.
HIV-infected patients on ART had approximately 4 and 1.5 greater odds of developing diabetes mellitus and metabolic syndrome, respectively.
Degludec is noninferior to glargine regarding the incidence of major cardiovascular events among patients with type 2 diabetes.
Adolescents with type 2 diabetes decreased HbA1c levels after using insulin pump therapy for a 3-month period.
Diabetes incidence rates in the US and glucose intolerance worldwide increased per 1°C increase in temperature.
The Stepping Up model of care produced a clinically and significantly significant improvement in HbA1c among adults with type 2 diabetes managed in primary care.
The position statement by the ADA incorporates updates in treatment and screening for patients with diabetic retinopathy.
Prediabetes does not always show clear symptoms; however, it can lead to type 2 diabetes, heart disease, or stroke.
Fasting glucose is specific but not sensitive, and HbA1c is neither sensitive nor specific.
The ACP has updated the 2012 guideline to provide clinical recommendations of oral pharmacologic treatment of type 2 diabetes.
The FDA has approved a continuous glucose monitoring system to replace fingerstick blood sugar testing in patients with diabetes.